NEW YORK, Dec. 14, 2021 /PRNewswire/ -- AIkido Pharma Inc.
(Nasdaq: AIKI) ("AIkido" or the "Company") today provided a status
update on its expansion of key patent applications into several
major ex-US territories worldwide.
For the Company's pancreatic cancer drug licensed from The
University Texas at Austin, in
which the Company currently seeks patent protection in the US, the
Company will now also seek protection on the licensed drug
formulation in China, India and the European Patent Office, with all
member countries designated, which includes all 27 EU member
countries plus 11 non-EU countries.
In connection with one of the two patent families relating to
antiviral treatments licensed from University
of Maryland, Baltimore (UMB), the Company filed a continuing
patent application under the Patent Cooperation treaty, which will
permit the Company seek patent protection simultaneously in the
multitude of worldwide member countries. For the other patent
family, the Company filed seeking to expand protection in the
European Patent Office, designating all member countries.
Anthony Hayes, CEO of AIkido,
stated, "Acquiring solid patent protection is the bedrock of drug
asset ownership and essential to acquiring potential future market
share in key countries around the world. At the appropriate times
and when it makes economic sense, we will continue seeking to
expand the territorial patent coverage on our licensed assets."
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a
biotechnology Company with a diverse portfolio of small-molecule
anticancer and antiviral therapeutics. The Company's platform
consists of patented technology from leading universities and
researchers, and we are currently in the process of developing an
innovative therapeutic drug platform through strong partnerships
with world renowned educational institutions, including
The University of Texas at
Austin and University of Maryland at Baltimore. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer, prostate
cancer. We are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also developing a
broad-spectrum antiviral platform that may potentially inhibit
replication of multiple viruses including Influenza virus, SARS-CoV
(coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas,
Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aikido-pharma-reports-filing-for-expanded-worldwide-patent-coverage-on-key-assets-301444313.html
SOURCE AIkido Pharma Inc.